Eton Pharmaceuticals Files 8-K/A for Asset Acquisition
Ticker: ETON · Form: 8-K/A · Filed: Nov 18, 2025 · CIK: 1710340
Sentiment: neutral
Topics: amendment, acquisition, financial-statements
TL;DR
Eton Pharma filed an amendment with updated financials for a Dec 2024 asset deal.
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K/A on November 18, 2025, to amend its previous filing regarding the completion of an acquisition or disposition of assets. The filing includes financial statements and exhibits related to this event, which occurred on December 19, 2024.
Why It Matters
This filing provides updated financial information and exhibits related to a past acquisition, which is crucial for investors to assess the company's financial health and strategic moves.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing providing financial statements and exhibits, not a new material event.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- December 19, 2024 (date) — Date of earliest event reported
- November 18, 2025 (date) — Filing Date
- 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208 (address) — Principal executive offices
FAQ
What is the purpose of this 8-K/A filing?
The purpose is to amend a previous 8-K filing to include financial statements and exhibits related to the completion of an acquisition or disposition of assets.
When was the original event related to this filing reported?
The earliest event reported was on December 19, 2024.
What type of information is being provided in this amendment?
The amendment provides financial statements and exhibits related to the acquisition or disposition of assets.
What is the filing date of this 8-K/A?
The filing date is November 18, 2025.
What is the principal business address of Eton Pharmaceuticals, Inc.?
The principal executive offices are located at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208.
Filing Stats: 762 words · 3 min read · ~3 pages · Grade level 9.8 · Accepted 2025-11-18 16:16:47
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20250314_8ka.htm (8-K/A) — 28KB
- ex_790801.htm (EX-99.1) — 115KB
- ex_790803.htm (EX-99.2) — 192KB
- 0001437749-25-035597.txt ( ) — 495KB
- eton-20241219.xsd (EX-101.SCH) — 3KB
- eton-20241219_def.xml (EX-101.DEF) — 12KB
- eton-20241219_lab.xml (EX-101.LAB) — 15KB
- eton-20241219_pre.xml (EX-101.PRE) — 12KB
- eton20250314_8ka_htm.xml (XML) — 3KB
01. Completion of Acquisition or Disposition of Assets
Item 2.01. Completion of Acquisition or Disposition of Assets. On December 20, 2024, Eton Pharmaceutical, Inc. (the "Company'') filed a Current Report on Form 8-K reporting that on December 1 9, 2024, the Company completed its purchase (the "Acquisition") of Increlex ("Increlex") from Ipsen S.A. ("Ipsen"). On March 7, 2025, the Company filed Amendment No. 1 to Form 8-K ("Amendment No. 1") amending the Form 8-K filed on December 20, 2024 (the "Original Report"). Amendment No. 1 was being filed to provide the status of filing the financial statements relating to the Increlex as required by Item 9.01 of Form 8-K. Amendment No. 1 amended Item 2.01 and included additional information under Item 8.01 and no changes have been made to the Original Report. This Current Report on Form 8-K/A amends the original Form 8-K filed on December 20, 2024 to provide the historical financial statements of the Acquisition required under Item 9.0l(a) of Form 8-K and the pro forma financial information required under Item 9.0l(b) of Form 8-K. Except as set forth herein, this amendment does not amend, modify or update the disclosure contained in the original Form 8-K (including the exhibits thereto).
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (a) Financial Statements of Businesses Acquired. The audited abbreviated financial statements of INCRELEX as of and for the years ended December 31, 2022 and 2023, and unaudited abbreviated financial statements of INCRELEX as of September 30, 2024 and for the nine months ended September 30, 2023 and 2024, in each case with the accompanying notes, together with the Independent Auditors' Report thereon, are filed as Exhibit 99.1 to this Current Report on Form 8-K/A and are incorporated herein by reference. (b) Pro Forma Financial Information. The unaudited pro forma condensed combined financial statements of the Company and INCRELEX as of and for the nine months ended September 30, 2023 and 2024 are included as Exhibit 99.2 to this Current Report on Form 8-K/A and are incorporated by reference herein. (d) Exhibits. Exhibit No. Description 99.1 Audited abbreviated financial statements of INCRELEX as of and for the years ended December 31, 2022 and 2023 and unaudited abbreviated financial statements of INCRELEX as of September 30, 2024 and for the nine months ended September 30, 2023 and 2024, including notes thereto and Independent Auditors' report thereon. 99.2 Unaudited pro forma condensed combined financial statements of the Company and INCRELEX for the nine months ended September 30, 2023 and 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 18, 2025 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 3